

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

Gillies

SERIAL NO.:

09/292,217

GROUP NO.:

164

FILING DATE:

April 15, 1999

EXAMINER:

DEL D 6 1999 NOTES

ENHANCEMENT OF ANTIBODY-CYTOKINE FUSION PROTEIN MEDIATED IMMUNE RESPONSES BY CO-ADMINISTRATION WITH ANGIOGENESIS INHIBITOR

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the provisions of 37 C.F.R. §1.97, Applicants hereby make of record the references listed on the accompanying Form PTO-1449 for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the references are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed (CHECK ONE):

\boxtimes	(1)	within three (3) months of the Filing Date or before the mailing date of the First Office Action on the merits; or
	(2)	after the period defined in (1) but before the mailing date of a Final Rejection or Notice of Allowance, and
		the requisite Statement is below, OR
		the requisite fee under Rule 1.17(p), namely \$240.00, is included herein, or
	(3)	after the mailing date of a Final Rejection or Notice of Allowance but before the payment of the Issue Fee, AND
		Applicant hereby Petitions the Commissioner to accept and consider the attached Information Disclosure Statement, AND
		the requisite Statement is below, AND

Information Disclosure St. Serial No.: 09/292,217

Page 2 of 2



It is respectfully requested that each of the references shown on the attached Form PTO-1449 be made of record in this application.

DEC 0 6 1999

STATEMENT

As required under §1.97(e), Applicants, through the undersigned, hereby state either that [check the appropriate space]:

- 1. [E]ach item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application **not more than** three months prior to the filing date of the Information Disclosure Statement; or
- [N]o item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

FEE AUTHORIZATION

Should any fee associated with the submission of this paper not be attached hereto as a check, the Commissioner is authorized to charge the missing fee to our Deposit Account, No. 20-0531. Any overpayments should be credited to said Deposit Account.

Date: December 2, 1999

Reg. No. 38,678

Tel. No.: (617) 248-7317 Fax No.: (617) 248-7100

GREENHAL4006/15.898925-1

Respectfully submitted.

Duncan A. Greenhalgh
Atty/Agent for Applicant(s)

Testa, Hurwitz, & Thibeault, LLP

High Street Tower 125 High Street

Boston, Massachusetts 02110